A Trial Investigating the Pharmacokinetic and Safety Profiles of NN1250 [insulin degludec] in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment and in Subjects With Normal Hepatic Function.
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 15 Sep 2009 New trial record